SEARCH

SEARCH BY CITATION

References

  • 1
    Gravallese EM & Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83: 703 9.
  • 2
    Greenstein AJ, Jarowitz HD, Scalar BD. The extra-intestinal manifestations of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401 12.
  • 3
    Haslock I & Wright V. The musculoskeletal complications of Crohn’s disease. Medicine 1973; 52: 217 25.
  • 4
    Protzer U, Duchmann R, Höhler T, et al. Enteropathic spondyloarthropathy in chronic inflammatory bowel disease: prevalence, pattern of manifestations and HLA-association. Ed Klin 1996; 91: 330 5.
  • 5
    Dougados M, Van Der Linden J, Juhlin R, et al. The European Spondyloarthropathy Group: The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34: 1218 26.
  • 6
    Mielants H, Veys EM, Goethals K, et al. Destructive lesions of small joints in seronegative spondyloarthropathies: relation to gut inflammation. Clin Exp Rheumatol 1990; 8: 23 7.
  • 7
    Huaux JP, Faissi R, De Bruyere M. HLA B27 in regional enteritis with and without ankylosing spondylitis or sacroilitis. J Rheumatol 1997; 4(Suppl. 3): 60 3.
  • 8
    Mallas EG, Mackintosh R, Asquith P. Histocompatibility antigens in inflammatory bowel disease: their clinical significance and their association with arthropathy with special reference to HLA B27. Gut 1976; 17: 906 10.
  • 9
    Scarpa R, Del Puente A, D’arienzo A, et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992; 19: 373 7.
  • 10
    Purrman J, Zeidler H, Bertrams J, et al. HLA antigens in ankylosing spondylitis associated with Crohn’s disease. Increased frequency of the HLA phenotype B27, B44. J Rheumatol 1988; 15: 1658 61.
  • 11
    Robinson WP, Van Der Linden SM, Khan MA, et al. HLA-Bw60 increases susceptibility by ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1989; 32: 1135 41.
  • 12
    Mielants H, Veys EM, Cuvelier C, De Vos M. Ilecolonoscopic findings in seronegative spondyloarthropathies. Br J Rheumatol 1988; 27: 95 105.
  • 13
    De Vos M, Cuvelier C, Mielants H, et al. Ileocolonscopy in seronegative spondyloarthropathy. Gastroenterology 1989; 96: 339 44.
  • 14
    Dougados M, Allemanni M, Tulliez M, et al. Iléocolonoscopie systhématique au cours des spondyloarthropathies séronégatives. Rev Rhum 1987; 54: 279 83.
  • 15
    Simenon G, Van Gossum A, Adler M, et al. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990; 17: 491 4.
  • 16
    Altomente L., Zoli A, Veneziania A, et al. Clinical silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 1994; 13: 565 70.
  • 17
    Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum 1994; 37: 23 31.
  • 18
    Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995; 22: 680 3.
  • 19
    Mielants H, Veys EM, Joos R, et al. Late onset pauciarticular juvenile chronic arthritis: relation to gut inflammation. J Rheumatol 1987; 14: 459 65.
  • 20
    Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987; 28: 394 401.
  • 21
    De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696 703.
  • 22
    Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63: 109 12.
  • 23
    Cuvelier C, Mielants H, De Vos M, et al. Major histocompatibility class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondyloarthropathies. Gut 1990; 31: 545 9.
  • 24
    Cuvelier CA, Quatacker J, Mielants H, et al. M-cells are damaged and increased in number in inflamed human ileal mucosa. Histopathology 1994; 24: 417 26.
  • 25
    Salmi M, Andrew DP, Butcher EC, et al. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995; 181: 137 49.
  • 26
    Adams DH & Shaw S. Leucocyte–endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831 6.
  • 27
    Picker LJ. Control of lymphocyte homing. Curr Opin Immunol 1994; 6: 394 406.
  • 28
    Elewaut D, De Vos M, De Keyser F, et al. Distinctive cell activation markers in colon from patients with Crohn’s disease and ulcerative colitis. Gastroenterology 1997; 112: A718.
  • 29
    Elewaut D, De Keyser F, Lazarovits A, et al. Inflamed synovial tissue from patients with spondyloarthropathy is enriched with activated T-cells carrying β7 integrins. Arthritis Rheum 1996; 39: S162.
  • 30
    Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints: distinct endothelial ligands in synovium mediate leukocyte subtype specific adhesion. J Clin Invest 1997; 99: 2165 72.
  • 31
    Kaufman HL, Fischer AH, Carroll M, Becker JM. Colonic ulceration associated with nonsteroidal antiinflammatory drugs. Dis Colon Rectum 1996; 39: 705 10.
  • 32
    Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). Arthritis Rheum 1996; 39: 2021 7.
  • 33
    Creemers MCW, Van Riel PLCM, Franssen MJAM, et al. Second-line treatment in seronegative spondyloarthropathies. Sem Arthritis Rheum 1994; 24: 71 81.
  • 34
    Taggart AJ, Gardiner P, McEvoy FM, et al. Which is the active moiety of sulphasalazine in ankylosing spondylitis? Arthritis Rheum 1996; 39: 1400 5.
  • 35
    Clegg Do, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996; 39: 2004 12.
  • 36
    Dougados M, Van Der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy. Arthritis Rheum 1995; 38: 618 27.
  • 37
    Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmocal Ther 1995; 9: 237 50.
  • 38
    Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417 22.
  • 39
    Roux C, Abithol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 156 60.
  • 40
    Vogelsang H, Klamert M, Resch H, Ferenci P. Dietary vitamin D intake in patients with Crohn’s disease. Wien Klin Wochenschr 1995; 19: 578 81.
  • 41
    Bjarnason I, MacPherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228 33.
  • 42
    Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993; 23: 95 104.
  • 43
    Clements D, Motley RJ, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 1055 60.
  • 44
    Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410 15.
  • 45
    Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis 1992; 37: 1396 403.
  • 46
    Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031 9.
  • 47
    Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71 6.
  • 48
    Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn’s disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997; 32: 226 32.
  • 49
    Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609 14.
  • 50
    Croucher PI, Vedi S, Motley RJ, et al. Reduced bone information bone formation in patients with oesteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993; 3: 236 41.
  • 51
    Hessov I, Mosekilde L, Melsen F, et al. Osteopenia with normal vitamin D metabolites after small bowel resection for Crohn’s disease. Scand J Gastroenterol 1984; 19: 691 6.
  • 52
    Lukert BP & Raisz LG. Glucocorticoid induced osteoporosis pathogenesis and management. Ann Intern Med 1990; 112: 352 64.
  • 53
    Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250 6.
  • 54
    Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313 19.
  • 55
    Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology 1982; 83: 1252 8.
  • 56
    Lin CL, Moniz C, Chambers TJ, Chow JWM. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111: 1263 71.
  • 57
    MacDonald BR & Gowen M. Cytokines and bone (review). Br J Rheumatol 1992; 31: 149 55.
  • 58
    Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543 6.
  • 59
    Francis RM, Peacock M, Aaron JE. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone 1986; 7: 261 8.
  • 60
    Silvennoinen JA, Lehtola JK, Niemelä SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996; 31: 364 71.
  • 61
    Bernstein CN, Seeger LL, Anton PA, et al.A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 777 86.
  • 62
    Adachi JD, Bensen WG, Brown J, et al. Intermittent eridronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl J Med 1997; 337: 382 7.
  • 63
    Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn’s disease. Gastroenterology 1997; 112: 1710 13.
  • 64
    MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD. Biochemical markers of bone turnover in seronegative spondyloarthropathy: relationship to disease activity. Br J Rheumatol 1997; 36: 50 3.
  • 65
    Marhoffer W, Stracke H, Masoud I, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995; 54: 556 9.